книга / 2016_Kaplan_USMLE_Step_1_Lecture_Notes_Pharmacology
.pdfAntibacterial Agents |
1 |
Learning Objectives
Apply the principles of antimicrobial chemotherapy to select the best treatment
Differentiate medications that inhibitor cell-wall synthesis, bacterial protein synthesis, and nucleic acid synthesis
Answer questions about unclassified antibiotics
Describe the differences between standard antibacterial agents and antitubercular drugs
PRINCIPLES OF ANTIMICROBIAL CHEMOTHERAPY
λBactericidal
λBacteriostatic
λCombinations:
–Additive
–Synergistic (penicillins plus aminoglycosides)
–Antagonistic (penicillin plus tetracyclines)
λMechanisms:
Table V-1-1. Mechanism of Action of Antimicrobial Agents
Mechanism of Action |
|
Antimicrobial Agents |
Inhibition of bacterial cell-wall |
|
Penicillins, cephalosporins, |
synthesis |
|
imipenem/meropenem, aztreonam, |
|
|
vancomycin |
Inhibition of bacterial protein |
|
Aminoglycosides, chloramphenicol, |
synthesis |
|
macrolides, tetracyclines, streptogramins, |
|
|
linezolid |
Inhibition of nucleic synthesis |
|
Fluoroquinolones, rifampin |
Inhibition of folic acid synthesis |
|
Sulfonamides, trimethoprim, |
|
|
pyrimethamine |
179
Section V λ Antimicrobial Agents
λ Resistance:
Table V-1-2. Mechanisms of Resistance to Antimicrobial Agents
Antimicrobial Agents |
|
Primary Mechanism(s) of Resistance |
Penicillins and cephalosporins |
Production of beta-lactamases, which cleave |
|
|
the beta-lactam ring structure; change in |
|
|
penicillin-binding proteins; change in porins |
|
Aminoglycosides (gentamicin, |
Formation of enzymes that inactivate drugs |
|
streptomycin, amikacin, etc.) |
via conjugation reactions that transfer acetyl, |
|
|
phosphoryl, or adenylyl groups |
|
Macrolides (erythromycin, |
Formation of methyltransferases that alter |
|
azithromycin, clarithromycin, |
drug binding sites on the 50S ribosomal |
|
etc.) and clindamycin |
subunit |
|
|
Active transport out of cells |
|
Tetracyclines |
Increased activity of transport systems that |
|
|
“pump” drugs out of the cell |
|
Sulfonamides |
Change in sensitivity to inhibition of target |
|
|
enzyme; increased formation of PABA; use of |
|
|
exogenous folic acid |
|
Fluoroquinolones |
Change in sensitivity to inhibition of target |
|
|
enzymes; increased activity of transport |
|
|
systems that promote drug efflux |
|
Chloramphenicol |
Formation of inactivating acetyltransferases |
INHIBITORS OF CELL-WALL SYNTHESIS
λ All cell-wall synthesis inhibitors are bactericidal.
|
|
|
|
|
Penicillins |
|
|
|
|
|
|
Cephalosporins |
|
||||||||||||||||||
|
|
|
|
H |
|
|
|
|
|
|
H |
|
|
|
|
|
|
|
|
||||||||||||
R |
|
|
|
|
|
|
|
|
|
|
|
R1 |
|
|
|
|
|
|
|
|
|
|
|
S |
|
||||||
N |
|
|
|
|
|
N |
|
|
|
|
|
|
|||||||||||||||||||
|
C |
|
|
|
|
|
|
|
|
S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
CH3 |
|
|
C |
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
O |
|
O |
|
|
N |
|
|
|
|
|
CH3 |
|
|
O |
|
O |
|
|
|
|
N |
|
CH2-R2 |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
COOH |
|
|
|
|
|
|
|
|
|
|
|
|
|
COOH |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure V-1-1. Beta-Lactam Antibiotics
180
Chapter 1 λ Antibacterial Agents
Imipenem and Meropenem
λMechanism of action:
−Same as penicillins and cephalosporins
−Resistant to beta-lactamases
λSpectrum:
– Gram-positive cocci, gram-negative rods (e.g., Enterobacter, Pseudomonas spp.), and anaerobes
−Important in-hospital agents for empiric use in severe life-threaten- ing infections
λPharmacokinetics:
−Imipenem is given with cilastatin, a renal dehydropeptidase inhibitor, which inhibits imipenem’s metabolism to a nephrotoxic metabolite
−Both drugs undergo renal elimination— ↓ dose in renal dysfunction
λSide effects:
−GI distress
−Drug fever (partial cross-allergenicity with penicillins)
−CNS effects, including seizures with imipenem in overdose or renal dysfunction
Aztreonam
λMechanism of action:
−Same as for penicillins and cephalosporins
−Resistant to beta-lactamases
λUses:
−IV drug mainly active versus gram-negative rods
−No cross-allergenicity with penicillins or cephalosporins
Vancomycin
λMechanism of action:
−Binding at the D-ala-D-ala muramyl pentapeptide to sterically hinder the transglycosylation reactions (and indirectly preventing transpeptidation) involved in elongation of peptidoglycan chains
−Does not interfere with PBPs
λSpectrum:
– MRSA
– Enterococci
– Clostridium difficile (backup drug)
λResistance:
−Vancomycin-resistant staphylococcal (VRSA) and enterococcal (VRE) strains emerging
−Enterococcal resistance involves change in the muramyl pentapeptide “target,” such that the terminal D-ala is replaced by D-lactate
183